Big Tech and Big Pharma Form AI Drug Development Infrastructure Alliance

Bristol Myers Squibb (BMY) has partnered with NVIDIA (NVDA) to build the largest artificial intelligence (AI) data center in the bio-healthcare sector. This collaboration, an expansion of their three-year partnership, aims to significantly enhance biological data processing capabilities and accelerate the discovery of new drug candidates by implementing NVIDIA's next-generation computing systems. This move aligns with the trend of global pharmaceutical companies like Roche and Eli Lilly adopting NVIDIA's supercomputing infrastructure. It demonstrates how AI technology has evolved from a mere supporting research tool to a core infrastructure component in drug research and development (R&D).

Samsung Biologics' GLP-1 Peptide CDMO Makes Major M&A Move

Samsung Biologics (207940.KS) has decided to fully acquire PolyPeptide Group (PPGN), a Swiss-based global peptide contract development and manufacturing organization (CDMO), for 1.46 billion Swiss francs (approximately $1.8 billion) in cash. The bid is priced at 44.31 Swiss francs per share, and the deal is expected to be completed within the year, subject to the unanimous approval of the PolyPeptide board of directors. This strategic decision aims to diversify the company's contract manufacturing portfolio, which has traditionally focused on antibody drugs and antibody-drug conjugates (ADCs), into the rapidly growing market for GLP-1 active pharmaceutical ingredients (APIs) used in obesity and diabetes treatments. By proactively addressing the increasing global peptide supply shortage and securing a captive pipeline, Samsung Biologics aims to solidify its leading position in the global CDMO market.

Scholar Rock's Apitegromab Faces Regulatory and Manufacturing Hurdles

Scholar Rock (SRRK)'s spinal muscular atrophy (SMA) treatment candidate, Apitegromab, is facing delays in its regulatory approval timeline due to manufacturing quality issues at the Indiana fill-finish facility. The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) last year due to concerns about the manufacturing facility, and a reinspection was conducted in April. However, the final approval decision is pending, with a target date of September 30 (PDUFA Date). The European Medicines Agency (EMA) has also stated that it will finalize the approval process only after the FDA has verified the corrective actions taken at the facility. This situation underscores the critical importance of regulatory compliance (cGMP) in contract manufacturing organizations (CMOs) for the commercial success of a biotech company's key pipeline assets, in addition to clinical efficacy.

Novartis' Fabhalta Receives Definitive Approval in the Rare Kidney Disease Market

Novartis (NVS)'s Factor B inhibitor, Fabhalta (active ingredient: iptacopan), has received traditional approval from the FDA for the treatment of primary IgA nephropathy (IgAN). This approval is based on data from 2024 demonstrating a reduction in proteinuria, which had previously led to accelerated approval. The company has now provided additional data demonstrating the efficacy of Fabhalta in slowing the decline in estimated glomerular filtration rate (eGFR), leading to the conversion to full approval. As a result, Fabhalta has established itself as the first oral complement inhibitor to receive full approval in the IgA nephropathy field, demonstrating its ability to preserve kidney function. Amidst competition from follow-on drugs such as Otsuka's Voyxact and Vera Therapeutics' Trutakna, Fabhalta is maximizing its market share with differentiated clinical data.

Dimerix Acquires Acute Kidney Injury Pipeline

Australian biotech Dimerix (DXB.AX) has acquired global rights to MTX652, a treatment candidate for acute kidney injury (AKI), from Mission Therapeutics. The deal includes an upfront payment of $5 million and potential milestone payments of up to $287 million, for a total value of $292 million. MTX652 selectively inhibits USP30, an enzyme that interferes with the breakdown of damaged mitochondria in cells, and has recently received FDA Investigational New Drug (IND) approval to begin Phase 2 clinical trials. Mission Therapeutics will focus its research efforts on central nervous system (CNS) diseases, while Dimerix will significantly strengthen its rare kidney disease portfolio. This is considered a mutually beneficial transaction.